GO:0043531 ADP binding: Mechanism and Genes

ADP binding (GO:0043531) is a molecular function that describes the selective, non-covalent interaction of a protein or protein complex with adenosine 5'-diphosphate (ADP). ADP is the product of ATP hydrolysis and a central currency of cellular energy status, so proteins that bind ADP are positioned at the intersection of energy sensing, motor activity, and signal transduction. The QuickGO definition is deliberately concise: binding to ADP, adenosine 5'-diphosphate. This simplicity masks the breadth of biology controlled by ADP binding, from the rotary catalysis of mitochondrial ATP synthase to the polymerization dynamics of actin and the licensing of DNA replication origins. For researchers, GO:0043531 is a useful annotation because it separates ADP-specific recognition from generic nucleotide binding. Many ADP-binding proteins also hydrolyze ATP or exchange nucleotides, and the ADP-bound state often represents an inhibited, primed, or waiting conformation. For example, high-affinity ADP binding to mitochondrial F1-ATPase is a well-established mechanism of catalytic inhibition, and ADP release is required for turnover. Similarly, ADP binding to the Saccharomyces cerevisiae origin recognition complex (ORC) modulates its interaction with origin DNA and contributes to replication control. ADP binding is also a target of pathogenic mimicry. Binary actin-ADP-ribosylating toxins bind host ADP-ribosylation factors and actin, then modify actin to disrupt the cytoskeleton. Mosquito salivary D7 proteins bind ADP and other biogenic amines to suppress host platelet aggregation and vasoconstriction, directly enhancing blood feeding. These examples show that GO:0043531 is not a narrow biochemical curiosity but a functional node relevant to infection, immunity, hemostasis, and metabolism.

In this article, ADP binding (GO:0043531) means the ability of a gene product to selectively bind adenosine 5'-diphosphate, the nucleotide formed when ATP loses one terminal phosphate. The term covers high-affinity binding sites on enzymes, motors, and regulatory complexes, and it is annotated in the molecular_function aspect of the Gene Ontology. It does not by itself imply catalysis, hydrolysis, or signaling; it describes the binding event. Synonyms include adenosine 5'-diphosphate binding and adenosine diphosphate binding.

ADP binding matters because ADP is not merely a waste product of ATP hydrolysis; it is a regulatory ligand whose binding and release can switch enzymes between active and inhibited states, control motor protein cycling, and coordinate DNA replication licensing. Because ADP levels report cellular energy charge, ADP-binding proteins act as metabolic sensors and effectors. In infection and immunity, ADP-binding proteins from pathogens and vectors manipulate host responses, as shown for binary actin-ADP-ribosylating toxins and mosquito D7 proteins. Understanding GO:0043531 therefore informs drug discovery, toxin biology, mitochondrial medicine, and cytoskeletal pharmacology.

The following genes and proteins represent major ADP-binding activities across energy metabolism, cytoskeleton, replication, and host-pathogen biology.

ADP binding is regulated by nucleotide availability, cellular energy charge, and protein conformational state. In mitochondria, ADP inhibition of ATP synthase depends on the ADP/ATP ratio and on the occupancy of catalytic and non-catalytic sites. In actin and myosin, ADP binding and release are coupled to polymerization, phosphate release, and force generation, so the nucleotide state is tuned by the motor cycle itself. In the origin recognition complex, ADP binding may modulate origin selection and replication timing. Pathogen and vector ADP-binding proteins are regulated by expression in salivary glands or during infection, and their activity can be modulated by host ligands.

Binary actin-ADP-ribosylating toxins bind host cells, are internalized, and modify actin, leading to cytoskeletal disruption and cell death. This mechanism underlies severe infections caused by Clostridium and related species, and it illustrates how ADP-binding and ADP-ribosylation can be pathogenic. Studying these toxins informs vaccine and therapeutic development.

ADP inhibition of H+-F(O)F(1)-ATP synthase is a physiological brake on ATP production, and dysregulation of this process is linked to mitochondrial dysfunction. Because ADP binding to F1-ATPase is central to this inhibition, mutations or conditions that alter ADP affinity can affect energy metabolism. This has implications for mitochondrial myopathies and metabolic disease.

ADP binding and release by myosin are essential steps in the cross-bridge cycle, and perturbations in this cycle can impair contractility. Cardiac and skeletal myosin isoforms are associated with inherited cardiomyopathies and muscle disorders, making ADP-binding kinetics a therapeutic target. Experimental models can test how mutations alter ADP affinity and force generation.

ADP binding by the origin recognition complex may influence replication licensing, and defects in licensing can cause genome instability. Although direct human disease links require further study, the conserved role of ORC in replication makes ADP binding relevant to cancer and developmental disorders. Model organisms such as Saccharomyces cerevisiae are useful for dissecting this regulation.

Direct ADP binding can be measured using radiolabeled ADP, fluorescent nucleotide analogues, isothermal titration calorimetry, or surface plasmon resonance. High-affinity binding of ADP and ADP analogues to mitochondrial F1-ATPase was established with such approaches. These assays define affinity, stoichiometry, and competition with ATP or other nucleotides.

Crystal structures and cryo-EM maps of ADP-bound complexes reveal the nucleotide pocket and conformational changes. Structural work on F1-ATPase, actin, myosin, and ORC has defined how ADP is coordinated. These data guide mutagenesis of ADP-binding residues.

ADP binding can be linked to function using ATPase assays, actin polymerization, motility assays, and replication origin firing assays. In infection biology, toxin uptake and ADP-ribosylation of actin are measured to connect binding to pathogenesis.

CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of ADP-binding proteins. Library screening can identify genes required for ADP-dependent processes, and bioinformatics can prioritize ADP-binding domains across genomes.

Researchers studying ADP binding-related genes often need to determine whether a candidate gene is causally involved in a phenotype, which requires precise genome editing rather than correlative expression data. EDITGENE provides the full toolkit to move from hypothesis to validated mechanism.

GO:0043531 ADP binding captures a fundamental molecular function that spans bioenergetics, cytoskeletal dynamics, DNA replication, and host-pathogen interactions. The authoritative definition is simple, but the biology is rich: ADP binding can inhibit, prime, or switch protein complexes, and it is exploited by toxins and vectors. For researchers, ADP binding is both a mechanistic question and a therapeutic opportunity. By combining precise CRISPR models with biochemical and structural methods, it is now possible to test causality for ADP-binding proteins in disease and physiology. EDITGENE supports this workflow with knockout, point-mutation, knock-in, overexpression, screening, and bioinformatics services tailored to ADP-binding targets.